IONS News and Press, Ionis Pharmaceuticals Inc. From 12/14/23

Ionis announces the appointment of Michael Yang to Board of Directors PR Newswire CARLSBAD, Calif. , Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the appointment of Michael Yang , an experienced biopharmaceutical ex...

2023-12-04 18:01:29 ET Summary Ionis Pharmaceuticals is focused on developing and strengthening its position in the oligonucleotide therapeutics sector. Oligonucleotide therapeutics offer a novel method for treating diseases by altering gene expression and targeting specific genes...

2023-11-30 00:50:33 ET Summary Tweedy, Browne's 13F portfolio value decreased by 2% to $1.87B this quarter. The largest position in the portfolio is Berkshire Hathaway, followed by Alphabet, Johnson & Johnson, Ionis Pharma, and Coca-Cola FEMSA. Tweedy, Browne made new stak...

2023-11-24 14:16:08 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Call Transcript Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Ionis says Angelman syndrome drug well tolerated in study ...

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imba...

2023-11-15 10:00:00 ET Summary Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, ...

2023-11-13 05:41:04 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) on Saturday shared positive clinical findings from an ongoing trial of its investigational antisense medicine, ION582, in Angelman syndrome (AS). ION582, which is being developed under a strategic collaboration wi...

Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome PR Newswire Part 1 of HALOS trial evaluating ION582 has completed enrollment with results expected in mid-2024 ION582 has been generally well tolerated at all dose levels, and pa...

Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema PR Newswire Continued treatment over two years with donidalorsen demonstrated sustained reduction in hereditary angioedema attacks and ...

2023-11-02 17:20:10 ET Ionis Pharmaceuticals, Inc. (IONS) Q3 2023 Earnings Conference Call November 02, 2023 11:30 AM ET Company Participants Wade Walke - Senior Vice President, Investor Relations Brett Monia - Chief Executive Officer Onaiza Cadoret - Chief Globa...